

Fungal Genetics Stock Center
Dept. of Microbiology
Univ. of Kansas Medical Center

Kansas City, KS 66103

Prints or other data relating to this deposit will aid the Stock Center and recipients of the strain.

Accession
number

SPECIES *Neurospora crassa*

MATING TYPE A

7922

GENOTYPE *esr-2 aga A* (*esr* = new locus, enhancer of spermidine requirement)

DESIGNATION OF MUTANT ALLELE(S) BMH422 UM906

LINKAGE GROUP(S) I, near mating type; VII

STRAIN DESIGNATION IF WILD TYPE N/A

YOUR STOCK NUMBER FOR THIS CULTURE IC2750-55A
include stock no. from other collections

ORIGIN OF STOCK UV mutagenesis of strain IC2552-65A (*spe-3*[JP120], *inl* [89601] *aga* [UM906] A), which is very leaky for the spermidine requirement yielded after selection for *Spe*, a strain carrying this additional mutation (*esr*[BMH]). This strain is a product of outcrossing the original multiple mutant, and does not have a spermidine requirement.

(for example - obtained from, genetic background, from cross with; or if collected from nature, collection point, substrate and collector.

PUBLISHED REFERENCES Davis, RH, P Lieu, JL Ristow (1994) *Neurospora* mutants affecting polyamine-dependent processes and basic amino acid transport mutants resistant to the polyamine inhibitor, α -difluoromethylornithine. *Genetics* 138:649-655. This publication does NOT assign BMH mutants the *esr* locus name.

IF UNPUBLISHED, please indicate strain of origin, mutagen, worker, genetic background, important characteristics

COMMENTS (special growth requirements, aberrations, heterokaryon compatibility special uses of strain, etc.)

Mutants of the BMH series are difficult to test; their action is to enhance their need for spermidine. Both combining them with leaky *spe* mutations and testing them on polyamine inhibitors (dicyclohexylamine and α -difluoromethylornithine) will demonstrate this. In addition, ascospores and (usually) conidia of BMH mutants germinate and then pause-often for more than one day-before continuing growth. Note: arginine imposes a spermidine requirement on *aga*-carrying strains.

YOUR NAME Rowland Davis

DATE February 2, 1995